Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 14, 2026, specifically the Company's Annual Meeting of Stockholders. The filing details the outcomes of four proposals voted upon by shareholders and the approval of a new equity incentive plan.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
The filing reports the following material corporate actions and voting outcomes:
- Shareholder Participation: Of 98,317,221 shares outstanding, 84,786,388 shares were represented at the meeting.
- Proposal 1 (Election of Class I Directors): Stockholders elected Emil D. Kakkis, Shehnaaz Suliman, and Daniel G. Welch. Notably, Dr. Suliman received significant withheld votes (7,772,860) compared to the other nominees.
- Proposal 2 (Third Amended and Restated 2023 Incentive Plan): Approved by stockholders. However, the vote was split, with 22,888,600 votes cast against the plan compared to 50,659,150 votes for.
- Proposal 3 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP with overwhelming support (84,551,399 votes for vs. 221,802 against).
- Proposal 4 (Say-on-Pay): Stockholders voted in favor of the advisory resolution to approve executive compensation (70,945,277 votes for vs. 2,594,517 against).
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It strictly reports the procedural results of the Annual Meeting and incorporates by reference the Third Amended and Restated 2023 Incentive Plan (Exhibit 10.1) and the 2026 Proxy Statement for further details.
Key Facts for Investor Verification
- Verify the specific terms of the Third Amended and Restated 2023 Incentive Plan in the 2026 Proxy Statement, given the significant number of votes cast against it.
- Review the rationale behind the high number of withheld votes for Director Shehnaaz Suliman in the 2026 Proxy Statement or subsequent press releases.
- Confirm the total number of shares authorized under the newly approved incentive plan to assess potential dilution.
- Note that this filing does not contain financial results; refer to the most recent 10-K or 10-Q for financial health metrics.